IMW 2021 | Optimal treatment sequencing for relapsed/refractory myeloma
Philippe Moreau, MD, Nantes University Hospital, Nantes, France, talks on optimizing the treatment sequence for patients with multiple myeloma. Prof. Moreau discusses the importance of considering lenalidomide-refractoriness after first relapse and the use of pomalidomide with bortezomib and dexamethasone (PomVd) or carfilzomib, and dexamethasone plus either daratumumab or isatuximab, for lenalidomide-refractory patients. For patients who remain lenalidomide-sensitive after first relapse, Prof. Moreau suggests daratumumab, lenalidomide and dexamethasone. For the second relapse, one strategy proposed is pomalidomide-dexamethasone or carfilzomib-dexamethasone with either daratumumab or isatuximab in conjunction with an anti-CD38 antibody. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
